Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Tenax Therapeutics Inc increased its cash reserves by 361.09%, or 7.67m. Cash Flow from Financing totalled 13.57m or -- of revenues. In addition the company used 5.90m for operations while cash from investing totalled 2.84k.
Cash flow per share | -13.32 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 4.53 |
---|---|
Tangible book value per share | 4.53 |
More ▼
Balance sheet in USDView more
Current ratio | 6.10 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0314 |
---|---|
Total debt/total capital | 0.0305 |
More ▼